Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Time slots for BIO Investor Forum are now posted (times are San Francisco time).
Resverlogix: Tuesday October 17 9:30 AM
Zenith: Wednesday October 18 11:00 AM